Viking Therapeutics Inc (VKTX · NASDAQ)

Viking Therapeutics (VKTX, $28.51) remains a pre-revenue clinical-stage biotech, with the stock down 21.6% over three months and trading 32.3% below its 52-week high. The company burned $125.2M in operating cash in the quarter ended June 30, 2026, against $125.8M in cash and just $4.1M in total debt, while posting a Q2 net loss of $128.0M — an improvement from the $158.3M loss in the prior quarter. VKTX has beaten estimates in only one of the last four quarters, though the June quarter's $-1.1 EPS topped consensus of $-1.21 by 9.1%. Attention is focused on the newly launched oral maintenance dosing study for obesity candidate VK2735, which runs alongside fully enrolled Phase 3 VANQUISH-1 and VANQUISH-2 trials; Canaccord Genuity maintains a Buy with a $114 target versus the $94.71 consensus.